Accretion Nutraveda Board Approves Unaudited Financial Results

Accretion Nutraveda Ltd announced the outcome of its Board Meeting held on October 31, 2026. The Board approved the unaudited financial results for the half-year ended September 30, 2026, along with the limited review reports from the statutory auditors. The financial results will be available on the company's website. The company is primarily engaged in the manufacture, process, trade, sale, purchase, import, export, assemble, distribute, formulate, develop, consult, test, and deal in all kinds of Drugs, Nutraceutical Wellness products, and related products. The company also provided an update on the utilization of proceeds from its Initial Public Offer (IPO).